International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients

Jean Jacques Body, Rob Coleman, Philippe Clezardin, Carla Ripamonti, Rene Rizzoli, Matti Aapro

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

A society of geriatric oncology (SIOG) task force reviewed information from the literature (in PubMed) on bisphosphonates in elderly patients with bone metastases until December 2005. Additional pertinent data were obtained from the manufacturers. Bisphosphonates are recommended in the elderly with bone metastases to prevent skeletal-related events. Intravenous formulations are preferred for the treatment of hypercalcaemia. It has been recognised that zoledronic acid, ibandronate and pamidronate can effectively contribute in relieving metastatic bone pain. Creatinine clearance should be monitored in every patient, and a less renally toxic agent should be used where evidence of similar efficacy is available. The assessment and optimisation of hydration status is recommended. Due to the risk from osteonecrosis of the jaw, routine oral examination and treatment of dental problems by a dental team is recommended before bisphosphonates. Physicians should choose the most appropriate bisphosphonate. Safety precautions are particularly important in elderly patients. Further research is needed in this population.

Original languageEnglish
Pages (from-to)852-858
Number of pages7
JournalEuropean Journal of Cancer
Volume43
Issue number5
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Medical Oncology
Diphosphonates
Geriatrics
pamidronate
zoledronic acid
Bone and Bones
Tooth
Neoplasm Metastasis
Oral Diagnosis
Osteonecrosis
Poisons
Hypercalcemia
Advisory Committees
Jaw
PubMed
Creatinine
Physicians
Safety
Pain
Therapeutics

Keywords

  • Bisphosphonates
  • Bone metastases
  • Bone pain
  • Clinical practice recommendations
  • Elderly
  • Renal safety
  • SIOG

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. / Body, Jean Jacques; Coleman, Rob; Clezardin, Philippe; Ripamonti, Carla; Rizzoli, Rene; Aapro, Matti.

In: European Journal of Cancer, Vol. 43, No. 5, 03.2007, p. 852-858.

Research output: Contribution to journalArticle

Body, Jean Jacques ; Coleman, Rob ; Clezardin, Philippe ; Ripamonti, Carla ; Rizzoli, Rene ; Aapro, Matti. / International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. In: European Journal of Cancer. 2007 ; Vol. 43, No. 5. pp. 852-858.
@article{b5ddb04890424272bebd410a42b0b26f,
title = "International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients",
abstract = "A society of geriatric oncology (SIOG) task force reviewed information from the literature (in PubMed) on bisphosphonates in elderly patients with bone metastases until December 2005. Additional pertinent data were obtained from the manufacturers. Bisphosphonates are recommended in the elderly with bone metastases to prevent skeletal-related events. Intravenous formulations are preferred for the treatment of hypercalcaemia. It has been recognised that zoledronic acid, ibandronate and pamidronate can effectively contribute in relieving metastatic bone pain. Creatinine clearance should be monitored in every patient, and a less renally toxic agent should be used where evidence of similar efficacy is available. The assessment and optimisation of hydration status is recommended. Due to the risk from osteonecrosis of the jaw, routine oral examination and treatment of dental problems by a dental team is recommended before bisphosphonates. Physicians should choose the most appropriate bisphosphonate. Safety precautions are particularly important in elderly patients. Further research is needed in this population.",
keywords = "Bisphosphonates, Bone metastases, Bone pain, Clinical practice recommendations, Elderly, Renal safety, SIOG",
author = "Body, {Jean Jacques} and Rob Coleman and Philippe Clezardin and Carla Ripamonti and Rene Rizzoli and Matti Aapro",
year = "2007",
month = "3",
doi = "10.1016/j.ejca.2006.12.006",
language = "English",
volume = "43",
pages = "852--858",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "5",

}

TY - JOUR

T1 - International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients

AU - Body, Jean Jacques

AU - Coleman, Rob

AU - Clezardin, Philippe

AU - Ripamonti, Carla

AU - Rizzoli, Rene

AU - Aapro, Matti

PY - 2007/3

Y1 - 2007/3

N2 - A society of geriatric oncology (SIOG) task force reviewed information from the literature (in PubMed) on bisphosphonates in elderly patients with bone metastases until December 2005. Additional pertinent data were obtained from the manufacturers. Bisphosphonates are recommended in the elderly with bone metastases to prevent skeletal-related events. Intravenous formulations are preferred for the treatment of hypercalcaemia. It has been recognised that zoledronic acid, ibandronate and pamidronate can effectively contribute in relieving metastatic bone pain. Creatinine clearance should be monitored in every patient, and a less renally toxic agent should be used where evidence of similar efficacy is available. The assessment and optimisation of hydration status is recommended. Due to the risk from osteonecrosis of the jaw, routine oral examination and treatment of dental problems by a dental team is recommended before bisphosphonates. Physicians should choose the most appropriate bisphosphonate. Safety precautions are particularly important in elderly patients. Further research is needed in this population.

AB - A society of geriatric oncology (SIOG) task force reviewed information from the literature (in PubMed) on bisphosphonates in elderly patients with bone metastases until December 2005. Additional pertinent data were obtained from the manufacturers. Bisphosphonates are recommended in the elderly with bone metastases to prevent skeletal-related events. Intravenous formulations are preferred for the treatment of hypercalcaemia. It has been recognised that zoledronic acid, ibandronate and pamidronate can effectively contribute in relieving metastatic bone pain. Creatinine clearance should be monitored in every patient, and a less renally toxic agent should be used where evidence of similar efficacy is available. The assessment and optimisation of hydration status is recommended. Due to the risk from osteonecrosis of the jaw, routine oral examination and treatment of dental problems by a dental team is recommended before bisphosphonates. Physicians should choose the most appropriate bisphosphonate. Safety precautions are particularly important in elderly patients. Further research is needed in this population.

KW - Bisphosphonates

KW - Bone metastases

KW - Bone pain

KW - Clinical practice recommendations

KW - Elderly

KW - Renal safety

KW - SIOG

UR - http://www.scopus.com/inward/record.url?scp=33847637152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847637152&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2006.12.006

DO - 10.1016/j.ejca.2006.12.006

M3 - Article

VL - 43

SP - 852

EP - 858

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 5

ER -